Title:
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
Excerpt:Guangzhou Gloria Biosciences...announced that its fully human anti-PD-1 monoclonal antibody, Zimberelimab injection (YuTuo, GLS-010) has received marketing approval from the China National Medical Products Administration (NMPA), as monotherapy for the treatment of recurrent or metastatic cervical cancer (R/M CC) patients with positive PD-L1 expression (CPS≥1) who progressed on or after platinum-based chemotherapy.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Excerpt:...- Before enrollment, try to provide enough tumor tissue samples (archived or fresh biopsy samples) to evaluate and confirm the expression of PD-L1 and to detect other biomarkers; Considering the accessibility of clinical specimens, there is...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Excerpt:...Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1),.The histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma....
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
Excerpt:...Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1)....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
An open, multi-center, single-arm phase II clinical study for evaluating the efficacy and safety of recombinant fully human anti-PD-1 monoclonal antibody (GLS-010 injection) in patients with recurrent or metastatic cervical cancer
Excerpt:...Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1); 4. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Excerpt:...Subjects agree to provide sufficient tumor tissue samples for PD-L1 expression detection; 9....
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
Excerpt:With a median follow-up of 2.9 months, 7 of 25 evaluable pts achieved a partial response (PR). The ORR was 28% (95% CI, 12.07-49.39), with 7 pts achieving a PR ( 3 of 7 confirmed), 3 pts achieving stable disease (SD) and 15 pts with progressive disease (PD)...
DOI:10.1200/JCO.2020.38.15_suppl.6039